Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Business Update

3 Jan 2012 07:00

RNS Number : 8394U
ViaLogy PLC
03 January 2012
 



ViaLogy PLC ("ViaLogy" or "the Company")

 

Business update

 

Pasadena, January 3, 2012. ViaLogy PLC (VIY LSE/AIM), a provider of reservoir characterization, geophysical imaging and hydrocarbon sizing services to global oil and gas Exploration and Production companies based on proprietary, patented active signal processing technology, reports substantial progress has been achieved in consolidating relationships with major oil and gas exploration companies on three continents during the last quarter of 2011. In Asia, a contract with a National Oil Company awaits government approval to transfer seismic information before it is signed. In the US, a pilot contract with a supermajor has been completed and acknowledged as positive by the client, and for a large independent exploration company a blind test determined porosity features across a 60 sq km prospect in Texas. In Europe, at the invitation of another supermajor, ViaLogy scientists briefed over 50 company geophysicists around the world on QuantumRD, its powerful computational weak signal processing technology which aids the discovery, characterization, and sizing of hydrocarbon deposits.

In updating the Company's progress to bring the technology to the attention of the O&G giants, CEO Robert W. Dean acknowledges that there have been time frustrations beyond ViaLogy's control; "Unforeseen delays unrelated to our work have affected the consummation of contracts," he said.

In Asia, ViaLogy expects contract awards from two global E&P companies. The first such contract, with a National Oil Company, the contract award process has been dictated by standard procedures and timelines already in place for work performed on government leased fields. Now, however, negotiations have been concluded and contract terms agreed. The final phase involves obtaining approval from the government for the export of seismic data to ViaLogy's US headquarters in Pasadena. In the second case, many similar rules apply both to leaseholder and ViaLogy, but the ViaLogy board believe that the contract process is now on track to award.

In the US, results from ViaLogy's pilot contract for its current supermajor client have been acknowledged as positive and have presented results and conclusions on porosity values that would be unattainable with technology now in use by the client. Their quantitative analysis continues, and should result in further contract work under our already-signed Master Services Agreement.

Another ViaLogy success, this one for a large US-based independent, determined porosity features across a 60 sq km prospect in Texas. In this blind test of the technology porosity values were determined in five Permian formations using seismic data from which other analysis techniques had been unable to extract this information. The client confirms this and is conducting further quantitative evaluation. Accurate predictions of porosity are fundamental in identifying hydrocarbon locations, and a measure of QuantumRD's ability to add breakthrough value in the seismic analysis industry.

Involvement in Europe resulted from an unsolicited approach to ViaLogy by a second supermajor in September. Now detailed technical examination is underway and has been ongoing for over three months. The process has extended to multiple locations, and the supermajor has engaged its most senior technical and scientific staff, as well as its operational management.

"Running this gauntlet of rigorous technical scrutiny takes time and concentration, but is at the heart of client recruitment for us in this 'big tent' part of the industry. It will serve ViaLogy well going forward, and should result in contracted project work," said Mr. Dean.

 

 

For further information:

 

ViaLogy PLC

Terry Bond, Chairman - UK & Europe +44 (0) 1235 834 734

Nominated Advisor to ViaLogy PLC (Seymour Pierce)

Mark Percy / Catherine Leftley, Corporate Finance +44 (0) 207 107 8000

Katie Ratner / Jeremy Stephenson, Corporate Broking +44 (0) 20-7107-8000

About ViaLogy:

ViaLogy provides reservoir characterization, geophysical imaging and hydrocarbon sizing services to global oil and gas customers based on proprietary, patented active signal processing technology. ViaLogy's QuantumRD platform assists clients in de-risking prospects over a broad range of subsurface lithologies and complex stratigraphies to generate drilling targets, position offsets and enhance recovery.

ViaLogy's core technology rapidly and accurately detects weak signals buried in high noise background and clutter, and is applicable to active/passive seismic, electromagnetic and magneto telluric data. By exploiting normally disregarded noise variations induced by changes in porosity, fluid presence and permeability across the formation, and adding computer-designed noise to the data, ViaLogy is able to amplify subtle noise variations to enhance areal and depth resolution in complex lithologies that are not achievable through conventional means. For more information on ViaLogy, visit www.vialogy.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRABLGDBIBGBGDD
Date   Source Headline
7th Feb 20177:00 amRNSSouthern Europe Business Update
10th Jan 20173:33 pmRNSResult of General Meeting
10th Jan 20177:15 amRNSHardman Research: Yourgene improves growth
21st Dec 20164:00 pmRNSPosting of Circular
21st Dec 20167:00 amRNSHalf year results
21st Dec 20167:00 amRNSConditional Acquisition of Yourgene Bioscience
21st Nov 20167:00 amRNSPremaitha establishes first service lab in Asia
31st Oct 20167:00 amRNSPremaitha welcomes UK Govt. decision on NIPT
27th Oct 20164:10 pmRNSResult of AGM
27th Oct 20167:00 amRNSAGM Statement
21st Oct 20167:00 amRNSGrant of Options
3rd Oct 20167:15 amRNSHardman Research: Excellent first year for IONA®
30th Sep 20163:38 pmRNSNotice of AGM
30th Sep 20167:00 amRNSFinal Results
23rd Sep 201610:42 amRNSHolding(s) in Company
23rd Sep 20168:50 amRNSNotice of results & appointment of broker
23rd Sep 20168:50 amRNSInvestment agreement extension with Thermo Fisher
8th Sep 20169:08 amRNSDirectorate Change
6th Jul 20167:00 amRNSDirectorate Change
4th Jul 20167:00 amRNSProgress on anti-trust objections to litigation
22nd Jun 20167:00 amRNSAdoption of Financial Reporting Standard (FRS) 101
22nd Apr 201610:45 amRNSUpdate on competitor patent litigation
20th Apr 201611:14 amRNSHardman Research: IONA sales & litigation update
20th Apr 20167:00 amRNSPatent Litigation Rescheduled
18th Apr 20161:13 pmRNSHardman & Co Issues Research Report
18th Apr 20161:03 pmRNSHardman & Co Issues Research Report
14th Apr 20167:00 amRNSHolding(s) in Company
13th Apr 20169:52 amRNSHolding(s) in Company
13th Apr 20167:00 amRNSHoldings in Company, Director's Shareholding
11th Apr 20167:00 amRNSTrading Update
29th Mar 20167:00 amRNSPremaitha announces tenth customer laboratory
21st Mar 20167:00 amRNSDistribution Agreements in the Middle East
9th Mar 20165:21 pmRNSHolding in Company, Directors' Dealing Replacement
9th Mar 20163:33 pmRNSHolding in Company, Directors' Dealings
9th Mar 20167:00 amRNSDistribution Agreement with GeNext - Russia
7th Mar 20167:00 amRNSAppointment of Joint Broker
3rd Feb 20167:00 amRNSPremaitha partners with Visional Medical in India
2nd Feb 20167:00 amRNSPremaitha partners with Leeds Hospitals NHS Trust
28th Jan 20167:00 amRNSHardman & Co Research Report: IONA®-Up and running
27th Jan 20167:00 amRNSTwo new customers signed for clinical lab service
26th Jan 20162:29 pmRNSUpdate on UK Litigation Timing
15th Jan 20167:00 amRNSPremaitha welcomes NSC recommendation on NIPT
8th Jan 201612:40 pmRNSUpdate on competitor patent litigation
18th Dec 20157:00 amRNSDirector/PDMR Shareholding
16th Dec 20155:53 pmRNSHolding(s) in Company
15th Dec 20157:00 amRNSHardman Issues Research Report
14th Dec 20157:00 amRNSInvestment Agreement with Thermo Fisher Scientific
14th Dec 20157:00 amRNSHalf Yearly Report
11th Dec 20157:00 amRNSNotice of Half Year Results
2nd Dec 20157:00 amRNSFirst IONA® testing service in France at LaboSud

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.